CRVO NASDAQ
CervoMed Inc.
1W: -3.0%
1M: -11.8%
3M: -12.5%
YTD: -71.2%
1Y: -68.4%
3Y: -75.7%
5Y: -93.7%
$2.22
-0.02 (-0.89%)
After Hours: $2.25 (+0.02, +1.13%)
Weekly Expected Move ±15.1%
$2
$2
$2
$3
$3
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -8.18.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$9.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$33.6M
52W Range2.13-10
Volume148,521
Avg Volume5,630,027
Beta-4.30
Dividend—
Analyst Ratings
Company Info
CEOJohn J. Alam
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2008-05-23
Websitecervomed.com
20 Park Plaza
Boston, MA 02116
US
Boston, MA 02116
US
617-744-4400
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodâbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Latest News
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Brookline Capital Markets Forecasts CervoMed Q3 Earnings
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Blackburn Kelly | A-Award | 19,100 | $2.24 | 2026-10-22 |
| De Rosch Mark | A-Award | 19,100 | $2.24 | 2026-10-22 |
| Winton Matthew | A-Award | 19,100 | $2.24 | 2026-10-22 |
| BOGER JOSHUA S | P-Purchase | 955,414 | $3.14 | 2026-06-11 |
| BOGER JOSHUA S | P-Purchase | 955,414 | $3.32 | 2026-06-11 |